Login to Your Account



Innovent Biologics preps phase III trials for Mabthera, Humira biosimilars in China

By Shannon Ellis
Staff Writer

Wednesday, September 14, 2016

SHANGHAI – Innovent Biologics Inc., of Suzhou, has kicked off two pivotal phase III trials in China for biosimilar antibodies of global blockbusters.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription